197 related articles for article (PubMed ID: 28442901)
1. Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study.
Monteagudo M; Roset M; Rodriguez-Blanco T; Muñoz L; Miravitlles M
Int J Chron Obstruct Pulmon Dis; 2017; 12():1145-1152. PubMed ID: 28442901
[TBL] [Abstract][Full Text] [Related]
2. Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD.
Manoharan A; Morrison AE; Lipworth BJ
Lung; 2016 Apr; 194(2):259-66. PubMed ID: 26758884
[TBL] [Abstract][Full Text] [Related]
3. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
Sethi S; Kerwin E; Watz H; Ferguson GT; Mroz RM; Segarra R; Molins E; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2019; 14():667-682. PubMed ID: 30962681
[TBL] [Abstract][Full Text] [Related]
4. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
Marin JM; Beeh KM; Clemens A; Castellani W; Schaper L; Saralaya D; Gunstone A; Casamor R; Kostikas K; Aalamian-Mattheis M
Int J Chron Obstruct Pulmon Dis; 2016; 11():1425-34. PubMed ID: 27418815
[TBL] [Abstract][Full Text] [Related]
5. Clinical benefit of two-times-per-day aclidinium bromide compared with once-a-day tiotropium bromide hydrate in COPD: a multicentre, open-label, randomised study.
Kamei T; Nakamura H; Nanki N; Minakata Y; Matsunaga K; Mori Y;
BMJ Open; 2019 Jul; 9(7):e024114. PubMed ID: 31350236
[TBL] [Abstract][Full Text] [Related]
6. Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data.
Mannino DM; Clerisme-Beaty EM; Franceschina J; Ting N; Leidy NK
Int J Chron Obstruct Pulmon Dis; 2018; 13():1515-1525. PubMed ID: 29785101
[TBL] [Abstract][Full Text] [Related]
7. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
Kerwin EM; Kalberg CJ; Galkin DV; Zhu CQ; Church A; Riley JH; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
[TBL] [Abstract][Full Text] [Related]
8. The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies.
Jones PW; Leidy NK; Hareendran A; Lamarca R; Chuecos F; Garcia Gil E
Respir Res; 2016 May; 17(1):61. PubMed ID: 27215749
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
[TBL] [Abstract][Full Text] [Related]
10. A Real-World Observational Study Examining the Impact of Aclidinium Bromide Therapy on the Quality of Life, Symptoms, and Activity Impairment of Patients with Chronic Obstructive Pulmonary Disease: The Greek ON-AIR Study.
Kostikas K; Vassilakopoulos TI; Tzanakis N; Konstantinidis AK; Kosmas EN; Papiris S; Steiropoulos P; Manali ED; Michaelides SA; Daskos G
Int J Chron Obstruct Pulmon Dis; 2020; 15():515-526. PubMed ID: 32184588
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
[TBL] [Abstract][Full Text] [Related]
12. Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.
Beier J; Mroz R; Kirsten AM; Chuecos F; Gil EG
Int J Chron Obstruct Pulmon Dis; 2017; 12():1731-1740. PubMed ID: 28652725
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of aclidinium in patients with COPD.
Reid DJ; Carlson AA
Int J Chron Obstruct Pulmon Dis; 2014; 9():369-79. PubMed ID: 24812502
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods.
Kwak MS; Kim E; Jang EJ; Kim HJ; Lee CH
Int J Chron Obstruct Pulmon Dis; 2015; 10():2365-76. PubMed ID: 26604734
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
Rogliani P; Calzetta L; Ora J; Lipsi R; Segreti A; Matera MG; Cazzola M
Eur J Pharmacol; 2015 Aug; 761():383-90. PubMed ID: 25952728
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.
Jones PW; Rennard SI; Agusti A; Chanez P; Magnussen H; Fabbri L; Donohue JF; Bateman ED; Gross NJ; Lamarca R; Caracta C; Gil EG
Respir Res; 2011 Apr; 12(1):55. PubMed ID: 21518460
[TBL] [Abstract][Full Text] [Related]
18. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.
Edwards SC; Fairbrother SE; Scowcroft A; Chiu G; Ternouth A; Lipworth BJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2851-2858. PubMed ID: 27920512
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
[TBL] [Abstract][Full Text] [Related]
20. Initiation of triple therapy maintenance treatment among patients with COPD in the US.
Simeone JC; Luthra R; Kaila S; Pan X; Bhagnani TD; Liu J; Wilcox TK
Int J Chron Obstruct Pulmon Dis; 2017; 12():73-83. PubMed ID: 28053518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
